Study: Pfizer Vax for Adolescents and Children Useless at Best

A pre-print study by C.D. Andrews et al titled “OpenSAFELY: Effectiveness of COVID-19 vaccination in children and adolescents” posted on 20 May 2024 has found no substantial benefit for children and adolescents in England who received the Pfizer COVID-19 “vaccine”.

The paper is 29 pages long. The main text is about 9 pages, the remaining are references, tables and figures.

The observational study analyzed data from NHS England’s OpenSAFELY platform. All adolescents aged 12–15 years and all children aged 5–11 years on 31 August 2021 were included, except for those who were “clinically vulnerable” and those who were infected within 30 days of vaccination.

Vaccinated individuals were matched with unvaccinated individuals.

• For adolescents: first dose vs unvaccinated, N = 410,463 per group; second dose vs single dose only, N = 220,929 per group.

• For children: first dose vs unvaccinated, N = 141,711 per group; second dose vs single dose only, N = 66,231 per group.

In other words, the sample is sufficiently big.

The effectiveness is measured as first dose compared to unvaccinated and second dose compared to first dose for A&E attendance, hospitalizations, amongst others.

No COVID-19-related deaths were recorded. There were 3 non-COVID-19-related deaths for adolescents who had received the first dose.

In short, whatever benefit the vaccine had waned within weeks. For example, for first dose vs unvaccinated in adolescents:

By 15 weeks the cumulative incidence of positive SARS-CoV-2 tests was similar in the first dose and unvaccinated groups. The 20-week risks per 10,000 were 1,961 (95% CI 1,932-1,990) and 1,979 (1,950-2,008) in the vaccinated and unvaccinated groups respectively. The IRR comparing vaccinated with unvaccinated adolescents was 0.74 (95% CI 0.72-0.75).

The incidence of COVID-19 hospitalisation was lower after first vaccination than in the unvaccinated group (IRR 0.58; 0.38-0.89). The 20-week risks per 10,000 were 3.09 (2.05-4.67) and 4.23 (3.05-5.87) respectively.

For second dose vs first dose in adolescents:

By 14 weeks the cumulative incidence of positive SARSCoV- 2 test was similar in the second and single dose groups. The 20-week risks per 10,000 were 850 (95% CI 802-899) and 898 (861-935) after second and single dose respectively. The IRR comparing second with single doses was 0.67 (95% CI 0.65-0.69).

Myocarditis and pericarditis cases were rare. For first dose vs unvaccinated in adolescents, 9 cases of pericarditis and 3 cases of myocarditis were recorded, and for second dose vs first dose in adolescents, 3 cases of pericarditis and no cases of myocarditis were recorded. For children, 3 cases of pericarditis were recorded for first dose vs unvaccinated.

It should be noted that all cases of myocarditis and pericarditis were of vaccinated individuals.

I am not a doctor but for a minor benefit that “waned by 14 weeks after vaccination”, no COVID-19-related deaths either way, and increased risk of myocarditis and pericarditis, the Pfizer “vaccine” is worse than a skinny decaf latter. All this for what is basically a bad cold (if even that) for adolescents and children.

Figure 1: Kaplan-Meier estimates of cumulative incidence and risk ratios of outcomes for adolescents.

Figure 2: Kaplan-Meier estimates of cumulative incidence and risk ratios of outcomes for children.

---

Be sure to subscribe to our mailing list so you get each new Opinyun that comes out!

---